Windsor Botanical Therapeutics Inc. is developing a botanical health product, extracted from the root of Taraxicum officinale, (dandelion) for sale as a complementary therapy for cancer. The extraction process was scaled up to Good Manufacturing Process (GMP) status and is currently being manufactured under GMP standards by Advanced Orthomolecular Research (AOR) of Calgary, AB. This complex extract has undergone preliminary analysis to identify key active components. WBTI intends to develop the material as a standardized botanical health product and, ultimately, an evidence based therapeutic. The product category, “Complementary Medicines for Cancer Therapy”, is estimated by Business Nutrition Journal to be a $1.1 billion market in the U.S.
WBTI is developing a botanical health product, extracted from the root of Taraxicum officinale, (dandelion) for sale as a complementary therapy for cancer. The extraction process was scaled up to Good Manufacturing Process (GMP) status and is currently being manufactured under GMP standards by Advanced Orthomolecular Research (AOR) of Calgary, AB. This complex extract has undergone preliminary analysis to identify key active components. WBTI intends to develop the material as a standardized botanical health product and, ultimately, an evidence based therapeutic. The product category, “Complementary Medicines for Cancer Therapy”, is estimated by Business Nutrition Journal to be a $1.1 billion market in the U.S.
Joseph Elliot, Chief Executive Officer, Director
Dr. Elliot is founding President & CEO of Windsor Botanical Therapeutics Inc. a developer and marketer of a breakthrough natural therapy for terminal cancer patients.
He is also Principal at Biopharm Management Inc. (BMI) a Toronto, Canada based firm providing short and long term management services to the biopharmaceutical industry. For the past 27 years Dr. Elliot has been a serial entrepreneur and former venture capitalist.
Dr. Elliot is a hands-on manager with skills and experience in all facets of the biopharmaceutical business including raising capital, financing, licensing, team building, drug development, manufacturing, regulatory affairs (FDA, Health Canada and BfArM). He has broad experience pharmaceuticals, biologicals and vaccines in oncology and infectious diseases.
Through BMI, Dr. Elliot is currently Managing Director of ERC USA, the North American subsidiary of ERC Belgium, a break-through developer of therapeutic cancer vaccines.
In the past 15 years, Dr. Elliot has raised over $30 million for a number of companies in which he played a leading management role including the founding and growing several biotech companies. These include President & CEO of Receptor Therapeutics Inc., President & CEO of LymphoSign Inc., Vice President & General Manager Operations for MDS Proteomics Inc.; Chief Operating Officer for MDS Ocata Inc.; Interim Chief Operating Officer of Exogen Neurosciences Inc. He is the founding President and Chairman of PhageTech Inc. of Montreal, Quebec which had a successful IPO under the name Targanta Therapeutics Corporation. He was also initial CEO of Cytochroma Inc., (which was subsequently acquired by OPKO in 2013). He is also a past director of Nexia Biotechnologies Inc. of Montreal, Quebec, and BIOSTAR Inc. of Saskatoon, Saskatchewan. From 1996 to 1999 he was a Vice President (Venture Capital) with MDS Capital Corp. specializing in early stage biotechnology investments.